Atomwise which operates an artificial intelligence (AI)-based drug discovery platform, has raised $163 million CAD ($123 million USD) in what it called an oversubscribed Series B financing round.
“With support from our new and existing investment partners, we will be able to leverage this to develop our own pipeline of small molecule drug programs, further grow our portfolio of joint-venture investments, and realize our vision to create better medicines that can improve the lives of billions of people,” said Abraham Heifets, CEO and co-founder of Atomwise.
Abraham Heifets (PhD, Computer Science, 2013) graduated from the A&S Centre for Entrepreneurship’s incubator and accelerator program in 2013.
Read the full article here: https://betakit.com/atomwise-raises-163-million-cad-series-b/